Guangdong Hybribio Biotech Co Ltd (SHE:300639) — Market Cap & Net Worth
Market Cap & Net Worth: Guangdong Hybribio Biotech Co Ltd (300639)
Guangdong Hybribio Biotech Co Ltd (SHE:300639) has a market capitalization of $548.70 Million (CN¥3.75 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #11623 globally and #3261 in its home market, demonstrating a 7.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangdong Hybribio Biotech Co Ltd's stock price CN¥5.80 by its total outstanding shares 646500674 (646.50 Million). See Guangdong Hybribio Biotech Co Ltd (300639) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Guangdong Hybribio Biotech Co Ltd Market Cap History: 2017 to 2026
Guangdong Hybribio Biotech Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $995.67 Million to $548.70 Million (5.57% CAGR).
Guangdong Hybribio Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangdong Hybribio Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.76x
Guangdong Hybribio Biotech Co Ltd's market cap is 0.76 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $995.67 Million | $479.09 Million | $93.21 Million | 2.08x | 10.68x |
| 2018 | $373.86 Million | $580.35 Million | $114.08 Million | 0.64x | 3.28x |
| 2019 | $758.11 Million | $729.39 Million | $147.29 Million | 1.04x | 5.15x |
| 2020 | $1.17 Billion | $1.35 Billion | $362.66 Million | 0.87x | 3.23x |
| 2021 | $1.16 Billion | $2.67 Billion | $852.16 Million | 0.43x | 1.36x |
| 2022 | $1.01 Billion | $5.60 Billion | $1.73 Billion | 0.18x | 0.59x |
| 2023 | $873.28 Million | $1.10 Billion | $140.47 Million | 0.79x | 6.22x |
| 2024 | $561.00 Million | $815.53 Million | -$654.88 Million | 0.69x | N/A |
| 2025 | $508.97 Million | $669.64 Million | -$130.94 Million | 0.76x | N/A |
Competitor Companies of 300639 by Market Capitalization
Companies near Guangdong Hybribio Biotech Co Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Guangdong Hybribio Biotech Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $215.67 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #168 globally with a market cap of $139.50 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #577 globally with a market cap of $46.51 Billion USD ( CN¥317.82 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #615 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $215.67 Billion | $574.03 |
| #168 | Danaher Corporation | NYSE:DHR | $139.50 Billion | $197.50 |
| #577 | WuXi AppTec Co Ltd | SHG:603259 | $46.51 Billion | CN¥128.50 |
| #615 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $567.84 |
Guangdong Hybribio Biotech Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Guangdong Hybribio Biotech Co Ltd's market cap moved from $995.67 Million to $ 548.70 Million, with a yearly change of 5.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥548.70 Million | +7.81% |
| 2025 | CN¥508.97 Million | -9.27% |
| 2024 | CN¥561.00 Million | -35.76% |
| 2023 | CN¥873.28 Million | -13.69% |
| 2022 | CN¥1.01 Billion | -12.94% |
| 2021 | CN¥1.16 Billion | -0.90% |
| 2020 | CN¥1.17 Billion | +54.69% |
| 2019 | CN¥758.11 Million | +102.78% |
| 2018 | CN¥373.86 Million | -62.45% |
| 2017 | CN¥995.67 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Guangdong Hybribio Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $548.70 Million USD |
| MoneyControl | $548.70 Million USD |
| MarketWatch | $548.70 Million USD |
| marketcap.company | $548.70 Million USD |
| Reuters | $548.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more